News

(LOS ANGELES) – Aneurysms, abnormal enlargement or ballooning in the wall of blood vessels can result in rupture and fatal bleeding. To treat aneurysms, it is essential to stop the blood flow to the affected area and prevent rupture of the vessel. Existing treatments for treating aneurysms include catheter-delivered stainless-steel coils or injectable biomaterials placed at the aneurysm site; however coils sometimes migrate, necessitating repeat procedures. Furthermore, there are problems with injectable biomaterials currently on the market, such as high cost, leakage, cytotoxic effects, and catheter clogs.

World leaders in academia and industry to discuss advances in precision medicine and translation into real world solutions

November 11, 2022

(LOS ANGELES) – The Terasaki Institute for Biomedical Innovation (TIBI) will be hosting the Terasaki Innovation Summit on March 8-10, 2023, at the UCLA Meyer & Renee Luskin Center in Los Angeles. This inaugural event will focus on improving technological and entrepreneurial translation of personalized medicines – bringing biomedical innovations from the laboratory to the real world.

By Ramadan Assi

In its tenth anniversary year, the annual WISH 2022 summit focused on four core themes: Sports and Health, Disability, Wellbeing, and the COVID-19 Legacy. The 2022 summit was unique, as it took place a few weeks before one of the most internationally anticipated sport events, the 2022 FIFA World Cup, which is scheduled to take place in Doha, Qatar, from November 20, 2022, to December 18, 2022.  

Aneurysms are weaknesses in the venous walls that require immediate attention, as they can result in the ballooning and bursting of the blood vessels.

September 20, 2022

(LOS ANGELES) - These critical medical conditions are often treated using catheter-delivered blocking agents. The blocking agents are delivered into the vessels to stop blood flow in the affected area until the vessel wall can heal. The blocking material can then be removed or allowed to degrade naturally.

By Megan Bettilyon

Not all science leads to innovative outcomes – in fact, it’s rare when the day-to-day work of a wet-lab comes across something new. You can, however, stack the deck in your favor by encouraging yourself, and your team, to try something new. Push the boundaries of what is known and be willing to accept failure as a step toward success. You can choose to be innovative; you can choose to surround yourself with people who think differently. This is when the magic happens. This is where Terasaki recently found a way to change the game in how we can bring novel therapeutics to market faster, cheaper, and more effectively.

Scientists devise novel methods in their microfluidic technology to produce optimized platforms for tissue and disease modeling

August 18, 2022

(LOS ANGELES) – A team of scientists, led by Xiling Shen, Ph.D., Chief Scientific Officer, and Professor at the Terasaki Institute for Biomedical Innovation (TIBI), has reached new levels in patient model development. They have developed improved methods for generating micro-organospheres (MOS) and have shown that these MOS have superior capabilities for a variety of clinical uses. As documented in a recent publication in Stem Cell Reports, their MOS can be used as patient avatars for studies involving direct viral infection, immune cell penetration and high-throughput therapeutic drug screening, something that is not obtainable with conventional patient-derived models.

August 11, 2022

(LOS ANGELES) – Scientists from the Terasaki Institute for Biomedical Innovation (TIBI) have developed a contact lens that can capture and detect exosomes, nanometer-sized vesicles found in bodily secretions which have the potential for being diagnostic cancer biomarkers. TThe lens was designed to have microchambers with antibodies that can capture exosomes found in tears. This antibody- conjugated signaling microchamber contact lens (ABSM-CL) can be stained for detection with nanoparticle-tagged specific antibodies for selective visualization. This offers a potential platform for cancer pre-screening and a supportive diagnostic tool that is easy, rapid, sensitive, cost-effective, and non-invasive.

August 10, 2022

(LOS ANGELES) – In a recent paper published in Cell, TIBI scientist Mohsen Akbari, Ph.D., reviews the most recent breakthroughs and innovations in tissue bioprinting. He also presents its various applications, the remaining challenges and outlook for the future.

Read More